Treatment of Candida nail infection with terbinafine
- PMID: 8959955
- DOI: 10.1016/s0190-9622(96)90120-6
Treatment of Candida nail infection with terbinafine
Abstract
Background: Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against Candida species are few and variable.
Objective: Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with Candida nail infection.
Methods: In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16.
Results: At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (> 50%), and failure in only 5% (one patient). Most nails were infected by Candida parapsilosis. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment.
Conclusion: The administration of terbinafine for 16 weeks is effective in the treatment of Candida nail infection. Liver enzyme values should be determined during the first month of treatment.
Similar articles
-
Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.J Am Acad Dermatol. 2001 Mar;44(3):479-84. doi: 10.1067/mjd.2001.110874. J Am Acad Dermatol. 2001. PMID: 11209118 Clinical Trial.
-
Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day.J Am Acad Dermatol. 1998 May;38(5 Pt 3):S57-63. doi: 10.1016/s0190-9622(98)70486-4. J Am Acad Dermatol. 1998. PMID: 9594939 Clinical Trial.
-
Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.Am J Geriatr Pharmacother. 2006 Mar;4(1):1-13. doi: 10.1016/j.amjopharm.2005.12.012. Am J Geriatr Pharmacother. 2006. PMID: 16730616 Clinical Trial.
-
Terbinafine: a review of its use in onychomycosis in adults.Am J Clin Dermatol. 2003;4(1):39-65. doi: 10.2165/00128071-200304010-00005. Am J Clin Dermatol. 2003. PMID: 12477372 Review.
-
Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.J Am Acad Dermatol. 1998 May;38(5 Pt 3):S32-36. doi: 10.1016/s0190-9622(98)70481-5. J Am Acad Dermatol. 1998. PMID: 9594934 Review.
Cited by
-
In vitro synergism of a water insoluble fraction of Uncaria tomentosa combined with fluconazole and terbinafine against resistant non-Candida albicans isolates.Pharm Biol. 2017 Dec;55(1):406-415. doi: 10.1080/13880209.2016.1242631. Pharm Biol. 2017. PMID: 27931150 Free PMC article.
-
Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.Mycopathologia. 2007 Jul;164(1):27-33. doi: 10.1007/s11046-007-9027-6. Epub 2007 Jun 6. Mycopathologia. 2007. PMID: 17551848
-
Onychomycosis in the elderly : drug treatment options.Drugs Aging. 2007;24(4):293-302. doi: 10.2165/00002512-200724040-00003. Drugs Aging. 2007. PMID: 17432924 Review.
-
Pharmacokinetics of antifungal agents in onychomycoses.Clin Pharmacokinet. 2001;40(6):441-72. doi: 10.2165/00003088-200140060-00005. Clin Pharmacokinet. 2001. PMID: 11475469 Review.
-
Current Management of Onychomycosis and Dermatomycoses.Curr Infect Dis Rep. 2000 Oct;2(5):438-445. doi: 10.1007/s11908-000-0074-0. Curr Infect Dis Rep. 2000. PMID: 11095890
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
